Pharming Group N.V. (PHARM.AS)
EUR 0.8
(-3.32%)
EUR 0.8
(-3.32%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 245.31 Million EUR | 10.35% |
| 2022 | 205.62 Million USD | 8.31% |
| 2021 | 189.85 Million EUR | -16.88% |
| 2020 | 228.39 Million EUR | 20.63% |
| 2019 | 189.33 Million EUR | 22.49% |
| 2018 | 154.57 Million EUR | 43.77% |
| 2017 | 107.51 Million EUR | 544.06% |
| 2016 | 16.69 Million EUR | 41.01% |
| 2015 | 11.83 Million EUR | -54.05% |
| 2014 | 25.76 Million EUR | 172.6% |
| 2013 | 9.45 Million EUR | -32.67% |
| 2012 | 14.03 Million EUR | 261.1% |
| 2011 | 3.88 Million EUR | 410.06% |
| 2010 | 762.06 Thousand EUR | -51.47% |
| 2009 | 1.57 Million EUR | 69.88% |
| 2008 | 924.35 Thousand EUR | -8.12% |
| 2007 | 1 Million EUR | 418.54% |
| 2006 | 194.01 Thousand EUR | -59.55% |
| 2005 | 479.68 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 55.58 Million USD | -32.26% |
| 2024 Q2 | 74.09 Million EUR | 33.5% |
| 2024 Q3 | 74.84 Million USD | 1.39% |
| 2023 Q3 | 66.66 Million USD | 21.43% |
| 2023 Q2 | 54.89 Million USD | 29.04% |
| 2023 Q4 | 81.21 Million USD | 21.84% |
| 2023 FY | 226.91 Million EUR | 10.35% |
| 2023 Q1 | 42.54 Million USD | -22.12% |
| 2022 Q4 | 54.62 Million USD | 0.71% |
| 2022 FY | 205.62 Million USD | 8.31% |
| 2022 Q1 | 46.61 Million USD | 1.9% |
| 2022 Q2 | 50.14 Million USD | 7.57% |
| 2022 Q3 | 54.23 Million USD | 8.16% |
| 2021 Q1 | 42.25 Million EUR | -39.84% |
| 2021 Q3 | 49.43 Million EUR | -0.61% |
| 2021 Q4 | 45.74 Million EUR | -7.46% |
| 2021 FY | 189.85 Million EUR | -16.88% |
| 2021 Q2 | 49.74 Million EUR | 17.73% |
| 2020 Q4 | 70.23 Million EUR | 20.01% |
| 2020 Q2 | 45.26 Million EUR | -16.73% |
| 2020 Q3 | 58.52 Million EUR | 29.28% |
| 2020 Q1 | 54.36 Million EUR | 0.0% |
| 2020 FY | 228.39 Million EUR | 20.63% |
| 2019 Q4 | 54.36 Million EUR | 17.29% |
| 2019 FY | 189.33 Million EUR | 22.49% |
| 2019 Q1 | 39.55 Million EUR | -2.03% |
| 2019 Q2 | 49.05 Million EUR | 24.01% |
| 2019 Q3 | 46.35 Million EUR | -5.51% |
| 2018 FY | 154.57 Million EUR | 43.77% |
| 2018 Q3 | 45.45 Million EUR | 40.34% |
| 2018 Q2 | 32.39 Million EUR | -10.89% |
| 2018 Q1 | 36.34 Million EUR | -11.15% |
| 2018 Q4 | 40.37 Million EUR | -11.19% |
| 2017 FY | 107.51 Million EUR | 544.06% |
| 2017 Q2 | 18.53 Million EUR | 12.19% |
| 2017 Q3 | 31.55 Million EUR | 70.23% |
| 2017 Q4 | 40.9 Million EUR | 29.66% |
| 2017 Q1 | 16.52 Million EUR | 137.9% |
| 2016 FY | 16.69 Million EUR | 41.01% |
| 2016 Q4 | 6.94 Million EUR | 78.86% |
| 2016 Q3 | 3.88 Million EUR | 15.65% |
| 2016 Q2 | 3.35 Million EUR | 33.8% |
| 2016 Q1 | 2.5 Million EUR | 9.47% |
| 2015 Q2 | 3.94 Million EUR | 104.61% |
| 2015 Q1 | 1.92 Million EUR | -90.77% |
| 2015 FY | 11.83 Million EUR | -54.05% |
| 2015 Q4 | 2.29 Million EUR | -37.62% |
| 2015 Q3 | 3.67 Million EUR | -6.83% |
| 2014 Q2 | 1.51 Million EUR | -22.51% |
| 2014 Q3 | 1.41 Million EUR | -6.6% |
| 2014 FY | 25.76 Million EUR | 172.6% |
| 2014 Q1 | 1.95 Million EUR | 39.52% |
| 2014 Q4 | 20.88 Million EUR | 1378.69% |
| 2013 Q3 | 1.67 Million EUR | -71.01% |
| 2013 Q4 | 1.39 Million EUR | -16.26% |
| 2013 FY | 9.45 Million EUR | -32.67% |
| 2013 Q1 | 619.81 Thousand EUR | -94.44% |
| 2013 Q2 | 5.76 Million EUR | 829.57% |
| 2012 Q3 | 653.26 Thousand EUR | -38.63% |
| 2012 FY | 14.03 Million EUR | 261.1% |
| 2012 Q4 | 11.14 Million EUR | 1606.3% |
| 2012 Q1 | 1.17 Million EUR | 20.8% |
| 2012 Q2 | 1.06 Million EUR | -9.11% |
| 2011 Q4 | 969.61 Thousand EUR | -4.89% |
| 2011 Q3 | 1.01 Million EUR | 1.95% |
| 2011 Q2 | 999.96 Thousand EUR | 11.36% |
| 2011 FY | 3.88 Million EUR | 410.06% |
| 2011 Q1 | 897.97 Thousand EUR | 694.64% |
| 2010 FY | 762.06 Thousand EUR | -51.47% |
| 2010 Q4 | -151.01 Thousand EUR | -141.81% |
| 2010 Q2 | 215.59 Thousand EUR | -22.42% |
| 2010 Q1 | 277.89 Thousand EUR | -64.94% |
| 2010 Q3 | 361.14 Thousand EUR | 67.51% |
| 2009 Q3 | 267.97 Thousand EUR | -23.49% |
| 2009 FY | 1.57 Million EUR | 69.88% |
| 2009 Q4 | 792.72 Thousand EUR | 195.82% |
| 2009 Q2 | 350.26 Thousand EUR | 153.86% |
| 2009 Q1 | 137.97 Thousand EUR | 0.0% |
| 2008 FY | 924.35 Thousand EUR | -8.12% |
| 2007 FY | 1 Million EUR | 418.54% |
| 2006 FY | 194.01 Thousand EUR | -59.55% |
| 2005 FY | 479.68 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -5186.983% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -5208.721% |
| Adocia SA | 2.15 Million EUR | -11310.047% |
| Aelis Farma SA | 9.05 Million EUR | -2609.476% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -7685.338% |
| genOway Société anonyme | 20.04 Million EUR | -1123.742% |
| IntegraGen SA | 12.53 Million EUR | -1856.668% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -81662.734% |
| Neovacs S.A. | 533.41 Thousand EUR | -45889.966% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -14488.987% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -1239120.044% |
| Sensorion SA | 4.74 Million EUR | -5072.1% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -82684.454% |
| TME Pharma N.V. | 17 Thousand EUR | -1442935.294% |
| Valbiotis SA | 4.73 Million EUR | -5083.097% |
| TheraVet SA | 1.07 Million EUR | -22655.425% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -13528.667% |
| argenx SE | 1.13 Billion EUR | 78.373% |
| BioSenic S.A. | 543 Thousand EUR | -45077.901% |
| Celyad Oncology SA | 102 Thousand EUR | -240405.882% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | -2.333% |
| Genfit S.A. | 28.56 Million EUR | -758.799% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -11654.48% |
| Innate Pharma S.A. | 51.9 Million EUR | -372.661% |
| Inventiva S.A. | 17.47 Million EUR | -1303.651% |
| MaaT Pharma SA | 2.22 Million EUR | -10910.592% |
| MedinCell S.A. | 9.16 Million EUR | -2578.122% |
| Nanobiotix S.A. | 30.05 Million EUR | -716.142% |
| Onward Medical N.V. | 532 Thousand EUR | -46012.03% |
| Oryzon Genomics S.A. | 14.19 Million EUR | -1628.599% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -10915.537% |
| Oxurion NV | 263 Thousand EUR | -93176.046% |
| Poxel S.A. | 1.98 Million EUR | -12283.443% |
| GenSight Biologics S.A. | 1.26 Million EUR | -19261.957% |
| Transgene SA | 1.18 Million EUR | -20619.257% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 95.329% |
| Valneva SE | 153.71 Million EUR | -59.595% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 6876.685% |